<DOC>
	<DOCNO>NCT00716495</DOCNO>
	<brief_summary>In open-label study patient advance melanoma 20 evaluable patient recruit . The drug substance , AGI-101H , whole cell , allogeneic melanoma vaccine , represent mixture ( 1:1 ratio ) two therapeutic gene modify human melanoma cell line , refer Mich1H6 Mich2H6 , gamma-irradiated render cell non-proliferative Patients receive treatment 26 week . Progression time point require systemic treatment , example chemotherapy cytokine lead withdrawal patient study . The dose chosen 5 x 107 viable cells/dose .</brief_summary>
	<brief_title>Safety Pharmacodynamic Study New Formulation , AGI - 101H Vaccine Treatment Advanced Melanoma</brief_title>
	<detailed_description>Total number patient : 20 evaluable patient enrol study . Dosage : 5 x 107 live cell . No dose modification plan . Administration : Subcutaneous ( s.c. ) Duration treatment : Patients receive treatment 26 week . Progression time point require systemic treatment , example chemotherapy cytokine lead withdrawal patient study . All survive patient AGITAM trial offer opportunity transfer follow-up treatment protocol AGI - 101H . In case treatment may continue every 4 - 8 week progression death withdrawal unless therapy contraindicate patient wish continue . Reference therapy : Not applicable . Description medicinal product : The drug substance , AGI-101H , whole cell , allogeneic melanoma vaccine , represent mixture ( 1:1 ratio ) two therapeutic genemodified human melanoma cell line , refer Mich1H6 Mich2H6 , gamma-irradiated render cell non-proliferative . There recommended International Non-proprietary ( INN ) Name drug substance . Methodology : In open-label study patient advance melanoma , one dose AGI - 101H vaccine administer s.c.. 20 evaluable patient recruit . An independent data monitoring committee ( DMC ) review safety data first 10 injection another 10 injection ( 20 injection total ) . Up second DMC meeting patient stay hospital 2 hour observation ; analysis 20 vaccination DMC review safety data may recommend revert normal outpatient set .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients must give sign informed consent participation study prior studyrelated procedure perform part normal medical care , understand consent may withdraw patient time without prejudice future medical care Age ≥18 year age ≤75 year age Histologically confirm , unresectable stage 3 4 measurable ( RECIST criterion ) , cutaneous melanoma unknown primary melanoma metastases Life expectancy least 30 week ECOG performance status X 1 Adequate renal liver function define serum creatinine total bilirubin level great 1.5 time Investigational Site 's upper normal laboratory limit Normal clot The patient willing able comply protocol duration study , include 2 hour follow observation injection ( DMC lift analysis first 20 injection ) course trial , examination punch biopsy vaccination sit 48 hr post vaccine 1 ( week 0 ) 8 ( week14 ) . Any previous participation another trial AGI 101 vaccine Ocular mucosal melanoma Pregnant breastfeeding woman , woman childbearing potential unless effective method contraception use ( lack childbearing potential met postmenopausal , surgically sterile , practice contraception oral contraceptive hormonal therapy [ e.g . hormone implant ] , intrauterine device , diaphragm spermicide condom spermicide , sexually inactive ) Radiotherapy target lesion immunotherapy ( include treatment Interferon Interleukin2 systemic glucocorticosteroids ) four week prior start study treatment . Any previous treatment systemic chemotherapy advance melanoma Brain metastases Major surgery four week prior start study treatment Patients poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , uncontrolled major seizure disorder , spinal cord compression , superior vena cava syndrome , psychiatric disorder prohibits obtain informed consent Patients know serologically positive Hepatitis B ( patient vaccinate Hepatitis B accept ) , Hepatitis C HIV States cause significant immunosuppression ( e.g . organ transplantation haemodialysis ) . Simultaneous participation study involve investigational drug participate study le 4 week prior start study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>